SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.190.0%1:30 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (32959)11/22/2009 5:39:13 PM
From: Ian@SI1 Recommendation  Read Replies (1) of 52153
 
Peter,

Many thanks for the abstract.

I hadn't looked yet as I was expecting first paper this week. Hopefully there will be a new paper with more detail within the next few days.

I have repeated to myself 100 times, "Correlation isn't causation".

But when I combine the P values in your abstract with the anecdotal cures claimed by those having the blockages removed, it certainly raises my hopes that this is a miraculous breakthrough in treating MS.

I can even imagine that the iron or other waste product buildup triggers a process or processes which lead directly or indirectly to the myelin attack.

If this does turn out to be a root cause, there could be a few biotechs that see shrinking revenues from Copaxone and lookalikes. Anyone care to guess at IV for BIIB?

Best regards,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News